Can I Take Saw Palmetto with Fosamax (Alendronate)?

Why This Combination Comes Up

Saw palmetto (Serenoa repens) is one of the most widely used herbal supplements in men over 50, primarily for benign prostatic hyperplasia (BPH) symptoms. Alendronate, sold as Fosamax, is a first-line bisphosphonate for osteoporosis prevention and treatment. Both are common in the same demographic: adults over 50 managing age-related conditions.

The Overlap Population

Osteoporosis affects roughly 10.2 million Americans aged 50 and older, according to National Health and Nutrition Examination Survey (NHANES) data published by the CDC. Male osteoporosis is underdiagnosed. Up to 2 million American men have the condition, and another 12 million are at risk [5]. Many of these same men take saw palmetto for urinary symptoms tied to BPH, which affects approximately 50% of men by age 60 [6].

Why Patients Ask

The concern is straightforward: will saw palmetto reduce alendronate's bone-protective effect, or will combining them produce side effects that neither would cause alone? The answer requires examining both pharmacokinetic (how the body processes each substance) and pharmacodynamic (how each substance acts on the body) pathways.

Pharmacokinetic Profile: No Overlap

Alendronate has an unusual pharmacokinetic profile compared to most oral drugs. It is absorbed poorly from the GI tract (oral bioavailability is approximately 0.6% under fasting conditions), is not bound to plasma proteins in a conventional sense, and is not metabolized by any hepatic enzyme system [1]. The drug deposits directly into bone hydroxyapatite, where it remains with a terminal half-life exceeding 10 years.

Why CYP450 Does Not Matter Here

Saw palmetto extract contains fatty acids (lauric acid, oleic acid, myristic acid) and phytosterols that show mild inhibition of CYP2D6 and CYP3A4 in vitro [7]. For drugs that depend on these enzymes for activation or clearance, this could be relevant. Alendronate does not. It passes through the body without hepatic biotransformation and is excreted unchanged in urine [1]. This means saw palmetto's CYP inhibitory activity has zero pharmacokinetic consequence for alendronate.

Absorption Considerations

Alendronate absorption is highly sensitive to co-administration with other substances. The FDA-approved labeling states that even coffee or orange juice reduces bioavailability by approximately 60% [8]. Calcium, magnesium, iron, and aluminum-containing antacids can chelate alendronate and block absorption almost entirely.

Saw palmetto supplements are typically oil-based soft gels. Taking them at the same moment as alendronate could theoretically reduce alendronate absorption through a fat-based matrix effect. The solution is simple: follow the standard alendronate dosing instruction to take the tablet with 6 to 8 ounces of plain water at least 30 minutes before any other oral intake, including supplements.

Pharmacodynamic Analysis: Separate Pathways

The pharmacodynamic question is whether saw palmetto's biological actions interfere with alendronate's mechanism at the tissue level. They do not act on the same pathways.

Alendronate's Mechanism

Alendronate inhibits farnesyl pyrophosphate synthase within osteoclasts, blocking the mevalonate pathway. This prevents osteoclast-mediated bone resorption. The Fracture Intervention Trial (FIT), a landmark randomized controlled trial (N=2,027), demonstrated that alendronate 10 mg daily reduced vertebral fracture risk by 47% over 3 years compared to placebo [9]. This mechanism is entirely independent of androgen metabolism or prostaglandin synthesis.

Saw Palmetto's Mechanism

Saw palmetto's primary pharmacological action is inhibition of 5-alpha reductase (types I and II), the enzyme that converts testosterone to dihydrotestosterone (DHT) [2]. A secondary action involves mild inhibition of cyclooxygenase, giving it weak anti-inflammatory and antiplatelet properties [3].

Neither 5-alpha reductase inhibition nor COX inhibition affects osteoclast function or bisphosphonate binding to hydroxyapatite. No published study has demonstrated that saw palmetto reduces bone mineral density or attenuates bisphosphonate efficacy.

The Androgen Question

One theoretical concern merits discussion. DHT plays a role in bone metabolism. Studies have shown that 5-alpha reductase inhibitors like finasteride (5 mg daily) do not significantly reduce bone mineral density over 4 years of follow-up [10]. Saw palmetto's 5-alpha reductase inhibition is considerably weaker than finasteride's. A Cochrane systematic review (N=5,222 across 32 trials) found that saw palmetto 320 mg daily produced effects on prostate symptoms no different from placebo [11]. If saw palmetto's androgen-modifying effects are too weak to reliably shrink prostate tissue, they are too weak to meaningfully affect bone density.

Risk Assessment: The Bleeding Question

The most clinically relevant interaction concern between saw palmetto and any co-administered drug is saw palmetto's antiplatelet activity. Several case reports have described bleeding events in patients taking saw palmetto alongside anticoagulants or antiplatelet agents.

What the Case Reports Show

A 2001 case report in the Journal of Internal Medicine described a 53-year-old man who experienced intraoperative hemorrhage during a craniotomy while taking saw palmetto [12]. A separate case report documented increased INR in a patient on warfarin who added saw palmetto [3]. These cases involved drugs with primary anticoagulant activity, not bisphosphonates.

Relevance to Alendronate

Alendronate has no anticoagulant or antiplatelet properties. It does carry a risk of upper GI irritation (esophagitis, gastric ulceration), with the FIT trial reporting upper GI adverse events in 47.5% of alendronate patients vs. 46.2% of placebo patients, a difference that was not statistically significant [9]. The concern would be if saw palmetto's mild antiplatelet effect increased the risk of GI bleeding in a patient already experiencing bisphosphonate-related GI irritation.

Practical Risk Level

This risk is theoretical and very small. The Natural Medicines Comprehensive Database rates the interaction between saw palmetto and antiplatelet/anticoagulant drugs as "moderate" based on case reports, not controlled trials. No case reports or controlled studies have documented bleeding events specifically from the combination of saw palmetto and a bisphosphonate. For patients who have a history of GI bleeding, peptic ulcer disease, or concurrent NSAID use, the conversation about saw palmetto's mild antiplatelet activity is worth having. For the typical patient on alendronate alone, this risk does not warrant avoiding the combination.

Dose Separation and Practical Administration

The correct approach to taking these two substances together is the same approach that applies to alendronate with any co-administered oral product.

The 30-Minute Rule

Alendronate must be taken first thing in the morning on a completely empty stomach with 6 to 8 ounces of plain water. The patient should remain upright (sitting or standing) for at least 30 minutes and not eat, drink, or take any other medication or supplement during that window [8]. This protects both esophageal safety and drug absorption.

When to Take Saw Palmetto

Saw palmetto can be taken with breakfast or any subsequent meal. Most clinical trials of saw palmetto (including the STEP trial by Bent et al., published in the New England Journal of Medicine, N=225) administered the supplement with food [13]. Taking it with a meal improves absorption of its lipophilic components and keeps it well-separated from the alendronate dosing window.

Weekly Alendronate Dosing

Most patients now take alendronate 70 mg once weekly rather than 10 mg daily. The Fosavance trial demonstrated equivalent efficacy and improved adherence with the weekly regimen [14]. This means the dose-separation requirement applies only one morning per week. On the other six days, saw palmetto can be taken at any time without any alendronate-related consideration.

Monitoring Recommendations

No special monitoring is required for patients taking both saw palmetto and alendronate beyond what each substance warrants independently.

For Alendronate

The American Association of Clinical Endocrinologists (AACE) recommends baseline DEXA scanning, repeat DEXA at 1 to 2 years to assess treatment response, and periodic assessment of serum calcium, 25-hydroxyvitamin D, and renal function [4]. Patients should report any new heartburn, difficulty swallowing, or retrosternal pain, which could indicate esophageal irritation.

For Saw Palmetto

No routine lab monitoring is standard for saw palmetto at doses of 160 to 320 mg daily. One important clinical note: saw palmetto may reduce serum PSA levels by approximately 8% based on a secondary analysis of the CAMUS trial data [15]. Clinicians ordering PSA tests should be aware of this potential confounder, though it does not interact with alendronate's mechanism.

When to Contact a Physician

Patients should contact their prescriber if they experience unusual bruising or bleeding (relevant to saw palmetto's antiplatelet activity), difficulty swallowing or persistent heartburn (relevant to alendronate's esophageal risk), or jaw pain or spontaneous dental problems (relevant to rare bisphosphonate-associated osteonecrosis of the jaw, reported at a rate of approximately 1 in 10,000 to 1 in 100,000 patient-years of oral bisphosphonate use) [16].

What to Do If You Are Already Taking Both

If you are currently taking saw palmetto alongside alendronate and have not experienced adverse effects, there is no evidence-based reason to stop either one. The checklist is short.

Confirm you are following the standard alendronate dosing protocol: empty stomach, plain water, 30 minutes upright before any food or supplement. Take saw palmetto with a later meal, not in the same 30-minute fasting window. Mention both substances to your prescriber so they are documented in your medication record. Continue standard DEXA monitoring on the schedule your clinician has established.

If you are about to start one of these while already taking the other, the same rules apply. No dose adjustment is needed for either substance. No additional lab tests are warranted beyond standard monitoring.

The Bottom Line on Hormonal Concerns

Some patients worry that saw palmetto's anti-androgenic properties could interfere with bone health during bisphosphonate therapy. The evidence does not support this concern. Finasteride, a pharmaceutical 5-alpha reductase inhibitor 10 to 50 times more potent than saw palmetto, showed no significant bone density loss over 4 years at the 5 mg dose used for BPH [10]. The AACE 2020 guidelines do not list 5-alpha reductase inhibitors (pharmaceutical or herbal) among medications that increase fracture risk or reduce bisphosphonate efficacy [4].

Saw palmetto 320 mg daily can be taken with alendronate 70 mg weekly, separated by the standard 30-minute fasting window, without expected pharmacokinetic interference, pharmacodynamic antagonism, or increased adverse event risk based on current evidence through 2026.